提醒

提醒专业图表

Cardiff Oncology Inc. (CRDF)

NasdaqCM: CRDF · 实时价格 · USD

0.90

-0.06 (-6.25%)

收盘价： Aug 17, 2026, 3:59 PM

0.93

+2.84%

盘后: 7:34 PM

-6.25% (1D)

买价	0.67
市值	70.35M
营收（TTM）	508K
净利润（TTM）	-40.08M
贝塔值	1.44
每股收益（TTM）	-0.57
市盈率（TTM）	n/a
预期市盈率	-1.55
市净率（TTM）	2.34
市销率（TTM）	138.48
Earnings Date	Nov 12, 2026

卖价	1.18
成交量	586,656
20日均量	1,572,922
开盘价	0.95
前收盘价	0.96
日内区间	0.90 - 0.96
52周区间	0.76 - 3.31
分析师	Buy
目标价	4 (344.44%)
分红	n/a
除息日	n/a

关于 CRDF

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Jul 27, 2004

员工人数 30

交易所 NasdaqCM

股票代码 CRDF

官网 https://www.cardiffoncology.com

公司完整简介

财务表现

2025年，Cardiff Oncology的营收为593K，较上一年的683K下降-13.18%。净利润为-45.85M，增长0.92%。

财务报表

分析师预测

根据7位分析师的评级，CRDF的平均评级为“Buy”。12个月目标价为4，较最新价格上涨空间344.44%。

股票预测

财报意外

Cardiff Oncology 已于 Aug 11, 2026 发布季度财报：

营收为 $41K 低于预期 $0, ， -62.39% 同比下滑.

每股收益为 -0.14 超出预期 0.02, ， 33.33% 同比增长.

下次财报发布时间

Cardiff Oncology Inc. 计划于以下时间发布财报 Nov 12, 2026, 盘中。
分析师预计营收为 ... 升级

新闻

1月前 · InvestorsHub

Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital

Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncol...

1月前 · Insider Monkey

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list. TheFly repor...

2月前 · Simply Wall St.

Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist

Over the last 7 days, the U.S. market has dropped by 1.0%, yet it has risen by 23% over the past year, with earnings forecasted to grow annually by 17%. In such a fluctuating market, identifying stock...

4月前 · MarketBeat

Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar

Cardiff Oncology (NASDAQ:CRDF) interim CEO Mani Mohindru outlined updated clinical results and development plans for the company’s investigational PLK1 inhibitor onvansertib during a webinar focused o...

5月前 · MarketBeat

Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC

Cardiff Oncology (NASDAQ:CRDF) used an appearance at Oppenheimer’s 36th Annual Healthcare Conference to highlight updated clinical results and its development plans for onvansertib, an oral, highly se...

第 1 页，共 2 页

Cardiff Oncology Inc. (CRDF)